World Economic Forum names BlackRock's Larry Fink, Roche's Andre Hoffmann as interim co-chairs
ReutersAug 15, 2025 5:12 PM
Aug 15 (Reuters) - The World Economic Forum said on Friday it has appointed BlackRock BLK.N CEO Larry Fink and Roche Holding's ROG.S Vice-Chair André Hoffmann as interim co-chairs of its board.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey
Related Articles
Costco FY2025 Q4 Earnings Preview: Decoding Growth Drivers and Market Bets Amid Sky-High Valuation
TradingKey - Since the release of Costco's fiscal 2025 third-quarter earnings report, its stock performance has slightly underperformed the S&P 500 index. After a significant year-to-date rally, the stock has entered a consolidation phase, exhibiting a contracting triangle pattern, reflecting...TradingKey
15 hours ago
Fed Rate Cuts: Will the Russell 2000 Outperform the S&P 500?
TradingKey - On 17 September, the Federal Reserve cut interest rates by 25 basis points, marking the official restart of the rate-cutting cycle. In theory, small-cap stocks, compared to large-cap stocks, benefit more from Fed rate cuts. This is because they are more reliant on external financing...TradingKey
16 hours ago
What Is Worldcoin? Why Did WLD Surge Suddenly, and What’s Next?
Worldcoin is evolving from a “hype token” into a foundational layer for global identity. Its fusion of biometrics, blockchain, and financial inclusion has earned growing recognition from users and institutions. If it can overcome technical hurdles, launch real-world payment use cases, and stabilizeTradingKey
Fri, Sep 12
Unlocking Gold’s Next Leg: $4,000 in Reach by 2025？
TradingKey - Gold has kicked off a fresh uptrend in early September, breaking out of months of compression and reclaiming key territory. The decisive move above $3,500 establishes a new support base and puts higher objectives back on the table for the weeks aheadTradingKey
Thu, Sep 4
From Ozempic to Wegovy: Growth and Risks Behind Novo Nordisk’s Q2 Performance
TradingKey - Novo Nordisk achieved revenue of $11.67 billion in Q2 of the 2025 fiscal year, a 19% increase year-over-year, but it fell short of market expectations. Growth was primarily driven by strong performance in obesity care and rare diseases.TradingKey
Thu, Aug 7
Tradingkey
